Osimertinib
Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes
Ikena OncologySmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benzenesulfonamide, N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]- Ikena Oncology | Phase 1 | CC |
Same molecule, other indications
Osimertinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →